Springworks Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
The Goldman Sachs Group and its subsidiary, Goldman Sachs & Co. LLC, reported a 0.0% beneficial ownership stake in Springworks Therapeutics, Inc. as of September 30, 2025.
The Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have disclosed a 5.6% beneficial ownership stake in SpringWorks Therapeutics, Inc.
Hudson Bay Capital Management LP and Sander Gerber have disclosed a 5.22% beneficial ownership stake in SpringWorks Therapeutics, Inc., including shares from call options.
Glazer Capital, LLC and Paul J. Glazer have reported that their beneficial ownership in SpringWorks Therapeutics, Inc. has fallen to 0.00%, triggering a Schedule 13G filing.
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a 1.7% beneficial ownership stake in SpringWorks Therapeutics Inc. as of April 30, 2025.
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has reported a passive beneficial ownership of 4.65% in Springworks Therapeutics, Inc. as of December 31, 2024.
SCHEDULE 13G/A: Vanguard Group Discloses 9.62% Stake in SpringWorks Therapeutics
The Vanguard Group has filed an amended Schedule 13G, reporting a 9.62% beneficial ownership stake in SpringWorks Therapeutics Inc. as of December 31, 2024.